mafosfamide has been researched along with carmustine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buschfort, C; Müller, MR; Rajewsky, MF; Seeber, S; Seiler, F; Thomale, J | 1 |
| Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P | 1 |
| Hansen, WK; Kelley, MR; Limp-Foster, M; Rosenquist, TA; Williams, DA; Xu, Y | 1 |
3 other study(ies) available for mafosfamide and carmustine
| Article | Year |
|---|---|
Capacity of individual chronic lymphatic leukemia lymphocytes and leukemic blast cells for repair of O6-ethylguanine in DNA: relation to chemosensitivity in vitro and treatment outcome.
Topics: Acute Disease; Carmustine; Cyclophosphamide; Cytarabine; DNA Repair; Doxorubicin; Drug Resistance; Ethylnitrosourea; Glutathione; Guanine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphocytes; Treatment Outcome | 1994 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies | 1998 |
Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Blotting, Northern; Carmustine; Cell Division; Cyclophosphamide; Cytoprotection; DNA; DNA Damage; DNA Repair; DNA-Formamidopyrimidine Glycosylase; Drug Interactions; Escherichia coli Proteins; Genetic Therapy; Genetic Vectors; Humans; Mice; N-Glycosyl Hydrolases; Thiotepa; Transfection; Transgenes | 2001 |